Search

Your search keyword '"A. Gershman"' showing total 72 results
Start Over Author "A. Gershman" Journal the journal of urology
72 results on '"A. Gershman"'

26. MP11-04 CONTEMPORARY INCIDENCE AND PREDICTORS OF OCCULT INGUINAL LYMPH NODE METASTASES IN MEN WITH CN0 PENILE CANCER

Author

Boris Gershman, Peter Chang, Simon P. Kim, Pooja Unadkat, Andrew J. Wagner, Ruslan Korets, Aaron Fleishman, and Aria F. Olumi

Subjects
medicine.medical_specialty, business.industry, Urology, Inguinal lymph nodes, Incidence (epidemiology), medicine.disease, Occult, Clinical Practice, Dissection, Increased risk, medicine, Penile cancer, Lymph, Radiology, business
Abstract

INTRODUCTION AND OBJECTIVE:Clinical practice guidelines recommend inguinal lymph node dissection (ILND) for men with clinically node-negative (cN0) penile cancer at increased risk of occult lymph n...

Published
2020
Full Text
View/download PDF

27. Outcomes Following Complete Surgical Metastasectomy for Patients with Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Author

Bradley C. Leibovich, Stephen A. Boorjian, Boris Gershman, M. Hassan Murad, William P. Parker, Harras B. Zaid, Brian A. Costello, Patricia J. Erwin, R. Houston Thompson, and Nida S. Safdar

Subjects
Male, medicine.medical_specialty, Urology, 030232 urology & nephrology, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, medicine, Carcinoma, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Carcinoma, Renal Cell, Survival analysis, Aged, Neoplasm Staging, Proportional Hazards Models, Proportional hazards model, business.industry, Hazard ratio, Metastasectomy, Middle Aged, medicine.disease, Prognosis, Survival Analysis, Kidney Neoplasms, Surgery, Treatment Outcome, 030220 oncology & carcinogenesis, Meta-analysis, Female, Radiology, business, Cohort study
Abstract

The benefit of complete surgical metastasectomy for patients with metastatic renal cell carcinoma remains controversial due to limited outcome data. We performed a systematic review and meta-analysis to determine whether complete surgical metastasectomy confers a survival benefit compared to incomplete or no metastasectomy for patients with metastatic renal cell carcinoma.Ovid Embase®, MEDLINE®, Cochrane and Scopus® databases were searched for studies evaluating complete surgical metastasectomy for metastatic renal cell carcinoma through January 19, 2016. Only comparative studies reporting adjusted hazard ratios (aHRs) for all cause mortality of incomplete surgical metastasectomy vs complete surgical metastasectomy were included in the analysis. Generic inverse variance with random effects models was used to determine the pooled aHR. Risk of bias was assessed with the Newcastle-Ottawa Scale.Eight published cohort studies with a low or moderate potential for bias were included in the final analysis. The studies reported on a total of 2,267 patients (958 undergoing complete surgical metastasectomy and 1,309 incomplete surgical metastasectomy). Median overall survival ranged between 36.5 and 142 months for those undergoing complete surgical metastasectomy, compared to 8.4 to 27 months for incomplete surgical metastasectomy. Complete surgical metastasectomy was associated with a reduced risk of all cause mortality compared with incomplete surgical metastasectomy (pooled aHR 2.37, 95% CI 2.03-2.87, p 0.001), with low heterogeneity (IComplete surgical metastasectomy for metastatic renal cell carcinoma is associated with improved survival compared with incomplete surgical metastasectomy based on meta-analysis of observational data. Consideration should be given to performing complete surgical metastasectomy, when technically feasible, in patients with metastatic renal cell carcinoma who are surgical candidates.

Published
2016

34. Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members

Author

Karthik Devarajan, Tianyu Li, Serge Ginzburg, Ryan N. Fogg, Daniel Canter, Steve Sterious, Boris Gershman, Robert G. Uzzo, John Walton, Anthony Corcoran, Marc C. Smaldone, Jay Simhan, and Alexander Kutikov

Subjects
Adult, Male, medicine.medical_specialty, medicine.drug_class, Cross-sectional study, Urology, Best practice, Injections, Subcutaneous, Specialty, Low molecular weight heparin, Compliance (psychology), Subcutaneous heparin, Surveys and Questionnaires, Medicine, Humans, Practice Patterns, Physicians', Societies, Medical, Internet, business.industry, Perioperative, Guideline, Venous Thromboembolism, Heparin, Low-Molecular-Weight, Middle Aged, United States, Cross-Sectional Studies, Family medicine, Practice Guidelines as Topic, Physical therapy, Urologic Surgical Procedures, Female, Guideline Adherence, Self Report, business
Abstract

Thromboprophylaxis with subcutaneous heparin or low molecular weight heparin is now an integral part of national surgical quality and safety assessment efforts, and has been incorporated into the current AUA Best Practice Statement. We evaluated familiarity and compliance with the AUA Best Practice Statement, assessed practice patterns in terms of perioperative thromboprophylaxis and specifically examined self-reported compliance in high risk patients undergoing radical cystectomy.An electronic survey was sent to AUA members with valid e-mail addresses (10,966). Associations between AUA Best Practice Statement adherence and factors such as urological specialty, graduation year and guideline familiarity were assessed using chi-square analyses and generalized estimating equations.With 1,210 survey responses the largest group of respondents was urological oncologists and/or laparoscopic/robotic specialists (26.0%). This group was more likely to use thromboprophylaxis than nonurological oncologists and/or laparoscopic/robotic specialists in high risk patients (OR 1.3, CI 1.1-1.5). Respondents aware of the AUA Best Practice Statement guidelines (50.7%) were more likely to use thromboprophylaxis (OR 1.4, CI 1.2-1.6). Although 18.1% of urological oncologists and/or laparoscopic/robotic specialists and 34.2% of nonurological oncologists and/or laparoscopic/robotic specialists avoided routine thromboprophylaxis in patients undergoing radical cystectomy, the former were more likely to use thromboprophylaxis (p0.0001) than other respondents. Urologists graduating after the year 2000 used thromboprophylaxis in high risk patients undergoing radical cystectomy more often than did earlier graduates (79.2% vs 63.4%, p0.0001).Although younger age and self-reported urological oncologist and/or laparoscopic/robotic specialist status correlated strongly with thromboprophylaxis use, self-reported adherence to AUA Best Practice Statement was low, even in high risk cases with clear AUA Best Practice Statement recommendations such as radical cystectomy. These data identify opportunities for quality improvement in patients undergoing major urological surgery.

Published
2013

49. Re

Author

Ehrlich, Richard M., primary, Fuchs, Gerhard, additional, and Gershman, Alex, additional

Published
1995
Full Text
View/download PDF

50. Re

Author

Gerhard J. Fuchs, Alex Gershman, and Richard M. Ehrlich

Subjects
medicine.medical_specialty, business.industry, General surgery, Urology, medicine, business
Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results